fashion -WSS

fashion

author：Wikipedia 2025-10-02 21:05:08 - browse：48277

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Trump Organization, Michael Cohen agree to settle million

WSS

Telehealth startups are trying to fill the menopause care vacuum

When a patient nears the end, a feared therapy can comfort

What is artificial intelligence? Experts weigh in

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

EMA weighs against approval for Mirati's lung cancer drug

Prosecutors say FTX founder Sam Bankman

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Caribou posts encouraging results on off

In age of alternative facts, a scholarly course on calling out crap

Trump Organization, Michael Cohen agree to settle million

Wildfire smoke exposes gaps in outdoor worker protections

Stanford president’s abrupt resignation sparks debate

Tori Bowie and the unacceptable rates of Black maternal death

How a Boston hospital is priming medical residents to use GPT

How to save PrEP access — and even expand it

Extensive review finds private equity owners jack up cost of care

hotspot

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Hey, doctors: Don't be no

Stanford president’s abrupt resignation sparks debate

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

EMA weighs against approval for Mirati's lung cancer drug

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

focus

hotspot

hotspot

leisure time